Strongbridge Biopharma plc Long Term Debt

Strongbridge Biopharma plc (SBBP) currently reports a long-term debt of $17M as of June 2021. That compares with $6.8M in the prior-year period — up 148.5% year over year. Use the charts on this page to explore Strongbridge Biopharma plc's long-term debt history and peer comparisons.

Strongbridge Biopharma plc's long-term debt increased from $6.8M to $17M — a 148.5% year-over-year increase (period ending June 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Strongbridge Biopharma plc reported $17M in long-term debt as of June 2021. That compares with $6.8M in the prior-year period — up 148.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $17M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Strongbridge Biopharma plc, and consider following SBBP for alerts when major investors trade the stock.

Strongbridge Biopharma plc is classified in the Healthcare sector. On long-term debt, it currently shows $17M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SBBP with unrelated industries.